The use of ciclosporin A in veterinary dermatology

Veterinary Journal

Volumn 193, Issue 2, 2012, Pages 317-325

  Kovalik, Marcel ^a   Thoday, Keith L ^a,b   van den Broek, Adri H M ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cat; Ciclosporin A; Dermatology; Dog; Pharmacology; Therapy

Indexed keywords

ATOPICA; CALCINEURIN; CYCLOSPORIN; CYCLOSPORIN A; ERYTHROMYCIN; ITRACONAZOLE; KETOCONAZOLE; OPTIMMUNE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREDNISOLONE; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ALOPECIA AREATA; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; BASOPHIL; CELL FUNCTION; DARIER DISEASE; DERMATITIS; DERMATOLOGY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; EOSINOPHIL; EOSINOPHILIC GRANULOMA; ERYTHEMA MULTIFORME; EXTERNAL OTITIS; FOOD DRUG INTERACTION; FURUNCULOSIS; GROWTH INHIBITION; HELPER CELL; HISTIOCYTIC SKIN DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS; MAST CELL; NEPHROTOXICITY; NONHUMAN; PANNICULITIS; PEMPHIGUS FOLIACEUS; PROTEIN SYNTHESIS INHIBITION; PRURITUS; PYODERMA; RECOMMENDED DRUG DOSE; REVIEW; SEBACEOUS GLAND DISEASE; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; STOMATITIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URTICARIA PIGMENTOSA; VETERINARY MEDICINE;

ANIMALS; CAT DISEASES; CATS; CYCLOSPORINE; DERMATOLOGIC AGENTS; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SKIN DISEASES;

CANIS FAMILIARIS; FELIDAE; ORYCTOLAGUS CUNICULUS;

EID: 84865866084     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2012.03.027     Document Type: Review

References (139)

1. Amatori F.M., Meucci V., Giusiani M., Soldani G., Corazza M., Giorgi M. Effect of grapefruit juice on the pharmacokinetics of cyclosporine in dogs. Veterinary Record 2004, 154:180-181.
2. Andrysek T., Masri M., Jegorov A., Veselsky Z., Matha V. Equoral, new cyclosporine drug delivery system, versus Neoral: A bioequivalence study in healthy volunteers. Transplantation Proceedings 2003, 35:207-209.
3. Arkhaven A., Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clinics in Dermatology 2003, 21:225-240.
4. Bardagi M., Lloret A., Fondati A., Ferrer L. Neutrophilic dermatosis resembling pyoderma gangrenosum in a dog with polyarthritis. Journal of Small Animal Practice 2007, 48:229-232.
5. Barrs V.R., Martin P., Beatty J.A. Antemortem diagnosis and treatment of toxoplasmosis in two cats on cyclosporin therapy. Australian Veterinary Journal 2006, 84:30-35.
6. Baumer W., Kietzmann M. Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes. Veterinary Dermatology 2007, 18:107-114.
7. Beatty J., Barrs V. Acute toxoplasmosis in two cats on cyclosporin therapy. Australian Veterinary Journal 2003, 81. 339-339.
8. Bernsteen L., Gregory C.R., Aronson L.R., Lirtzman R.A., Brummer D.G. Acute toxoplasmosis following renal transplantation in three cats and a dog. Journal of the American Veterinary Medical Association 1999, 215:1123-1126.
9. Blackwood L., German A.J., Stell A.J., O'Neill T. Multicentric lymphoma in a dog after cyclosporine therapy. Journal of Small Animal Practice 2004, 45:259-262.
10. Bloom P.B. Canine and feline eosinophilic skin diseases. Veterinary Clinics of North America: Small Animal Practice 2006, 36:141-160.
11. Brazis P., Barandica L., Garcia F., Clough G.F., Church M.K., Puigdemont A. Dermal microdialysis in the dog: In vivo assessment of the effect of cyclosporin A on cutaneous histamine and prostaglandin D2 release. Veterinary Dermatology 2006, 17:169-174.
12. Breathnach R.M., Baker K.P., Quinn P.J., McGeady T.A., Aherne C.M., Jones B.R. Clinical, immunological and histopathological findings in a subpopulation of dogs with pododermatitis. Veterinary Dermatology 2005, 16:364-372.
13. Bruner S.R. Updates in therapeutics for veterinary dermatology. Veterinary Clinics of North America: Small Animal Practice 2006, 36:39-58.
14. Buice R.G., Gurley B.J., Stentz F.B., Sidhu P., McClellan T., Williams J.W. Cyclosporine disposition in the dog. Comparison of radioimmunoassay with high-performance liquid chromatographic assay and pharmacokinetics following intravenous administration. Transplantation 1985, 40:483-488.
15. Bunikowski R., Gerhold K., Brautigam M., Hamelmann E., Renz H., Wahn U. Effect of low-dose cyclosporin a microemulsion on disease severity, interleukin-6, interleukin-8 and tumor necrosis factor alpha production in severe pediatric atopic dermatitis. International Archives of Allergy and Immunology 2001, 125:344-348.
16. Bunikowski R., Staab D., Kussebi F., Brautigam M., Weidinger G., Renz H., Wahn U. Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: Clinical and immunological effects. Pediatric Allergy and Immunology 2001, 12:216-223.
17. Bussmann C., Bieber T., Novak N. Systemic therapeutic options for severe atopic dermatitis. Journal of the German Society of Dermatology 2009, 7:205-219.
18. Campana C., Regazzi M.B., Buggia I., Molinaro M. Clinically significant drug interactions with cyclosporin. An update. Clinical Pharmacokinetics 1996, 30:141-179.
19. Choc M.G. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral vs. Sandimmune. International Journal of Dermatology 1997, 36:1-6.
20. Christians U., Sewing K.F. Cyclosporin metabolism in transplant patients. Pharmacology and Therapeutics 1993, 57:291-345.
21. Cirillo R., Triggiani M., Siri L., Ciccarelli A., Pettit G.R., Condorelli M., Marone G. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. Journal of Immunology 1990, 144:3891-3897.
22. Clarke K., McCall C., Steffan J., Wassom D. The effects of cyclosporin A and oral prednisolone on flea allergen specific serum IgE and intradermal tests in experimentally sensitized laboratory Beagles. Veterinary Dermatology 2003, 14:248.
23. Cockerill G.W., Bert A.G., Ryan G.R., Gamble J.R., Vadas M.A., Cockerill P.N. Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT. Blood 1995, 86:2689-2698.
24. Dahlinger J., Gregory C., Bea J. Effect of ketoconazole on cyclosporine dose in healthy dogs. Veterinary Surgery 1998, 27:64-68.
25. de Rie M.A., Bos J.D. Cyclosporine immunotherapy. Clinics in Dermatology 1997, 15:811-821.
26. DeFeo M.L., Dubey J.P., Mather T.N., Rhodes R.C. Epidemiologic investigation of seroprevalence of antibodies to Toxoplasma gondii in cats and rodents. American Journal of Veterinary Research 2002, 63:1714-1717.
27. Donatsch P., Ryffel B. Pharmacokinetics of cyclosporine in toxicological studies. Transplantation Proceedings 1986, 18:71-76.
28. Doust R., Griffiths L.G., Sullivan M. Evaluation of once daily treatment with cyclosporine for anal furunculosis in dogs. Veterinary Record 2003, 152:225-229.
29. Ducharme M.P., Provenzano R., Dehoorne-Smith M., Edwards D.J. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. British Journal of Clinical Pharmacology 1993, 36:457-459.
30. Dunn J., Golden D., Van Buren C.T., Lewis R.M., Lawen J., Kahan B.D. Causes of graft loss beyond two years in the cyclosporine era. Transplantation 1990, 49:349-353.
31. Ellis C.N., Gorsulowsky D.C., Hamilton T.A., Billings J.K., Brown M.D., Headington J.T., Cooper K.D., Baadsgaard O., Duell E.A., Annesley T.M., Turcotte J.G., Voorhees J.J. Cyclosporine improves psoriasis in a double-blind study. Journal of the American Medical Association 1986, 256:3110-3116.
32. Faerber L., Braeutigam M., Weidinger G., Mrowietz U., Christophers E., Schulze H.J., Mahrle G., Meffert H., Drechsler S. Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients. American Journal of Clinical Dermatology 2001, 2:41-47.
33. Fahr A. Cyclosporin clinical pharmacokinetics. Clinical pharmacokinetics 1993, 24:472-495.
34. Farrell A.M., Antrobus P., Simpson D., Powell S., Chapel H.M., Ferry B.L. A rapid flow cytometric assay to detect CD4+ and CD8+ T-helper (Th) 0, Th1 and Th2 cells in whole blood and its application to study cytokine levels in atopic dermatitis before and after cyclosporin therapy. British Journal of Dermatology 2001, 144:24-33.
35. Favrot, C., 2004. Adverse events following short-term cyclosporine therapy: Results of a meta-analysis of 609 cases. In: Proceedings of the Atopica Symposium, 5th World Congress of Veterinary Dermatology, Vienna, Austria, pp. 16-21.
36. Fischer J.R., Harkin K.R., Freeman L.C. Concurrent administration of water-soluble vitamin E can increase the oral bioavailability of cyclosporine A in healthy dogs. Veterinary Therapeutics 2002, 3:465-473.
37. Fisher G.J., Duell E.A., Nickoloff B.J., Annesley T.M., Kowalke J.K., Ellis C.N., Voorhees J.J. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media. Journal of Investigative Dermatology 1988, 91:142-146.
38. Font A., Bardagi M., Mascort J., Fondevila D. Treatment with oral cyclosporin A of a case of vesicular cutaneous lupus erythematosus in a rough collie. Veterinary Dermatology 2006, 17:440-442.
39. Fontaine J., Heimann M. Idiopathic facial dermatitis of the Persian cat: Three cases controlled with cyclosporine. Veterinary Dermatology 2004, 15:64.
40. Fontaine J., Olivry T. Treatment of canine atopic dermatitis with cyclosporine: A pilot clinical study. Veterinary Record 2001, 148:662-663.
41. Freeman D.J. Pharmacology and pharmacokinetics of cyclosporine. Clinical Biochemistry 1991, 24:9-14.
42. Fromm M.F. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. International Journal of Clinical Pharmacology and Therapeutics 2000, 38:69-74.
43. Gregory C.R., Madewell B.R., Griffey S.M., Torten M. Feline leukemia virus-associated lymphosarcoma following renal transplantation in a cat. Transplantation 1991, 52:1097-1099.
44. Groves M., Harrington K., Taboada J. Frequently asked questions about zoonoses. Textbook of Veterinary Internal Medicine 2000, 388-389. WB Saunders, Philadelphia, USA. Fifth Ed. S.J. Etinger, E.C. Feldman (Eds.).
45. Guaguère E. Efficacy of cyclosporin in the treatment of idiopathic sterile nodular panniculitis in two dogs. Veterinary Dermatology 2000, 11:22.
46. Guaguère E., Fontaine J. Efficacy of cyclosporin in the treatment of feline urticaria pigmentosa: Two cases. Veterinary Dermatology 2004, 15:63.
47. Guaguère E., Prélaud P. Efficacy of cyclosporine in the treatment of 12 cases of eosinophilic granuloma complex. Veterinary Dermatology 2000, 11:S31.
48. Guaguère E., Steffan J., Olivry T. Cyclosporin A: A new drug in the field of canine dermatology. Veterinary Dermatology 2004, 15:61-74.
49. Guo J., Ping Q., Chen Y. Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmune Neoral. International Journal ofPharmaceutics 2001, 216:17-21.
50. Gupta A.K., Brown M.D., Ellis C.N., Rocher L.L., Fisher G.J., Baadsgaard O., Cooper K.D., Voorhees J.J. Cyclosporine in dermatology. Journal of the American Academy of Dermatology 1989, 21:1245-1256.
51. Hall J., Waisglass S., Yager J. Oral cyclosporin in the treatment of polypoid proliferative otitis externa in a cocker spaniel: A case report. Veterinary Dermatology 2002, 14:223.
52. Hardie R.J., Gregory S.P., Tomlin J., Sturgeon C., Lipscomb V., Ladlow J. Cyclosporine treatment of anal furunculosis in 26 dogs. Journal of Small Animal Practice 2005, 46:3-9.
53. Hatfield S.M., Roehm N.W. Cyclosporine and FK506 inhibition of murine mast cell cytokine production. Journal of Pharmacology and Experimental Therapy 1992, 260:680-688.
54. Hill D.E., Chirukandoth S., Dubey J.P. Biology and epidemiology of Toxoplasma gondii in man and animals. Animal Health Research Reviews 2005, 6:41-61.
55. Ho S., Clipstone N., Timmermann L., Northrop J., Graef I., Fiorentino D., Nourse J., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Clinical Immunology and Immunopathology 1996, 80:S40-S45.
56. House A.K., Guitian J., Gregory S.P., Hardie R.J. Evaluation of the effect of two dose rates of cyclosporine on the severity of perianal fistulae lesions and associated clinical signs in dogs. Veterinary Surgery 2006, 35:543-549.
57. Jassies-van der Lee A., van Zeeland Y., Kik M., Schoemaker N. Successful treatment of sebaceous adenitis in a rabbit with ciclosporin and triglycerides. Veterinary Dermatology 2009, 20:67-71.
58. Katayama M., Katayama R., Kamishina H. Effects of multiple oral dosing of itraconazole on the pharmacokinetics of cyclosporine in cats. Journal of Feline Medicine and Surgery 2010, 12:512-514.
59. Kelly P., Kahan B.D. Review: Metabolism of immunosuppressant drugs. Current Drug Metabolism 2002, 3:275-287.
60. Kovalik M., van den Broek A.H. The use of ciclosporin in canine and feline dermatology. Part 2. UK Vet 2010, 15:49-54.
61. Kovalik M., Wilkoek P., Szczepanik M., Pomorski Z., Kozak M., Kovalikova M. Cyclosporine - The new drug in treatment of canine atopic dermatitis. Zycie Weterynaryjne 2007, 82:59-62.
62. Kovalik M., Taskun I., Pomorski Z., Kozak M., Pomorska D., Szcepanik M., Wilkolek P., Palenik L., Shaw D.J., van Den Broek A.H.M., Thoday K.L. Evaluation of a human generic formulation of ciclosporin in the treatment of canine atopic dermatitis - A prospective, blinded study. Veterinary Record 2011, 20:537.
63. Kovalik M., Thoday K.L., Handel G.I., Bronsvoort B.M.d., Evans H., Van den Broek A.H., Mellanby R.J. Ciclosporin therapy disturbs glucose homeostasis in dogs with atopic dermatitis. Veterinary Dermatology 2011, 22:173-180.
64. Ku Y.M., Min D.I., Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: Does the formulation difference matter?. Journal of Clinical Pharmacology 1998, 38:959-965.
65. Lapin M. CVT update: Feline toxoplasmosis. Kirk's Current Veterinary Therapy XII 1995, 309-314. W.B. Saunders, Company; Philadelphia, USA. J. Bonagura (Ed.).
66. Last R.D., Suzuki Y., Manning T., Lindsay D., Galipeau L., Whitbread T.J. A case of fatal systemic toxoplasmosis in a cat being treated with cyclosporin A for feline atopy. Veterinary Dermatology 2004, 15:194-198.
67. Latimer K.S., Rakich P.M., Purswell B.J., Kircher I.M. Effects of cyclosporin A administration in cats. Veterinary Immunology and Immunopathology 1986, 11:161-173.
68. Leather H., Boyette R.M., Tian L., Wingard J.R. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biology of Blood and Marrow Transplantation 2006, 12:325-334.
69. Linek M., Boss C., Haemmerling R., Hewicker-Trautwein M., Mecklenburg L. Effects of cyclosporine A on clinical and histologic abnormalities in dogs with sebaceous adenitis. Journal of the American Veterinary Medical Association 2005, 226:59-64.
70. Liu C., Zhu S., Zhou Y., Wei Y., Pei Y. In situ intestinal absorption of cyclosporine A solid dispersion in rats. Drug Development and Industrial Pharmacy 2008, 34:627-631.
71. London N.J., Farmery S.M., Will E.J., Davison A.M., Lodge J.P. Risk of neoplasia in renal transplant patients. Lancet 1995, 346:403-406.
72. Maeda H., Takahashi M., Nakashima K., Fujino Y., Ohno K., Tsujimoto H., Takahashi K., Kanamura A., Fukamachi T. Treatment of five dogs with pemphigus foliaceus with cyclosporine and prednisolone. Veterinary Dermatology 2008, 19:51.
73. Marsella R., Olivry T. The ACVD task force on canine atopic dermatitis (XXII): Non-steroidal anti-inflammatory pharmacotherapy. Veterinary Immunology and Immunopathology 2001, 81:331-345.
74. Mason J. Renal side-effects of cyclosporin A. British Journal of Dermatology 1990, 122:71-77.
75. Masri M.A., Andrysek T., Matha V. The role of generics in transplantation. Transplantation Proceedings 2003, 35:2745-2747.
76. Masri M.A., Haberal M., Rizvi A., Stephan A., Bilgin N., Naqvi A., Barbari A., Kamel G., Zafar N., Emiroglu R., Colak T., Manzoor K., Matha V., Kamarad V., Rizk S., Itany A.R., Shehedeh I. The pharmacokinetics of Equoral versus Neoral in stable renal transplant patients: A multinational multicenter study. Transplantation Proceedings 2004, 36:80-83.
77. Masri M.A., Haberal M., Rizvi A., Stephan A., Bilgin N., Naqvi A., Barbari A., Kamel G., Zafar N., Emiroglu R., Colak T., Manzoor K., Matha V., Kamarad V., Rost M., Rizk S., Hazime A., Perlik F. Switchability of Neoral and Equoral according to Food and Drug Administration rules and regulations. Transplantation Proceedings 2005, 37:2988-2993.
78. Mathews K.A., Ayres S.A., Tano C.A., Riley S.M., Sukhiani H.R., Adams C. Cyclosporin treatment of perianal fistulas in dogs. Canadian Veterinary Journal - Revue Vétérinaire Canadienne 1997, 38:39-41.
79. Mathews K.A., Sukhiani H.R. Randomized controlled trial of cyclosporine for treatment of perianal fistulas in dogs. Journal of the American Veterinary Medical Association 1997, 211:1249-1253.
80. Mathews K.G., Gregory C.R. Renal transplants in cats: 66 cases (1987-1996). Journal of the American Veterinary Medical Association 1997, 211:1432-1436.
81. Matsuda S., Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000, 47:119-125.
82. Mauldin E.A., Morris D.O., Brown D.C., Casal M.L. Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: Disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment. Veterinary Dermatology 2010, 21:373-382.
83. McAnulty J.F., Lensmeyer G.L. The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. Veterinary Surgery 1999, 28:448-455.
84. Mehl M.L., Kyles A.E., Craigmill A.L., Epstein S., Gregory C.R. Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. Journal of Veterinary Pharmacology and Therapeutics 2003, 26:349-354.
85. Miniscalco A., Lundahl J., Regardh C.G., Edgar B., Eriksson U.G. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. Journal of Pharmacology and Experimental Therapy 1992, 261:1195-1199.
86. Mouatt J.G. Cyclosporin and ketoconazole interaction for treatment of perianal fistulas in the dog. Australian Veterinary Journal 2002, 80:207-211.
87. Navarro L., Verde M.T., Ortunez A., Basurco A. Leishmaniasis reactivation in an atopic dog treated with cyclosporine A. Veterinary Dermatology 2008, 19:1-83.
88. Noli C., Scarampella F. Prospective open pilot study on the use of ciclosporin for feline allergic skin disease. Journal of Small Animal Practice 2006, 47:434-438.
89. Noli C., Toma S. Three cases of immune-mediated adnexal skin disease treated with cyclosporin. Veterinary Dermatology 2006, 17:85-92.
90. Novartis, 2003. Freedom of Information NADA 141-218 Atopica. Novartis Animal Health. Atopica, pp. 1-22.
91. Oliveira A.M., Obwolo M.J., van den Broek A.H., Thoday K.L. Focal metatarsal sinus tracts in a Weimaraner successfully managed with ciclosporin. Journal of Small Animal Practice 2007, 48:161-164.
92. Olivry T., Power H.T., Woo J.C., Moore P.F., Tobin D.J. Anti-isthmus autoimmunity in a novel feline acquired alopecia resembling pseudopelade of humans. Veterinary Dermatology 2000, 11:261-270.
93. Olivry T., Rivierre C., Jackson H.A., Murphy K.M., Davidson G., Sousa C.A. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: A blinded randomized prednisolone-controlled trial. Veterinary Dermatology 2002, 13:77-87.
94. Olivry T., Steffan J., Fisch R.D., Prelaud P., Guaguere E., Fontaine J., Carlotti D.N. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. Journal of the American Veterinary Medical Association 2002, 221:370-377.
95. O'Neill T., Edwards G.A., Holloway S. Efficacy of combined cyclosporine A and ketoconazole treatment of anal furunculosis. Journal of Small Animal Practice 2004, 45:238-243.
96. Oran A., Marshall J.S., Kondo S., Paglia D., McKenzie R.C. Cyclosporin inhibits intercellular adhesion molecule-1 expression and reduces mast cell numbers in the asebia mouse model of chronic skin inflammation. British Journal of Dermatology 1997, 136:519-526.
97. Palmeiro B.S., Morris D.O., Goldschmidt M.H., Mauldin E.A. Cutaneous reactive histiocytosis in dogs: A retrospective evaluation of 32 cases. Veterinary Dermatology 2007, 18:332-340.
98. Patricelli A.J., Hardie R.J., McAnulty J.E. Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. Journal of the American Veterinary Medical Association 2002, 220:1009-1016.
99. Peterson A., Torres S., Rendahl A. Frequency of urinary tract infection in dogs treated with oral ciclosporin: A retrospective study of 87 cases. Veterinary Dermatology 2011, 22:291-292.
100. Plumb D. Plumb's Veterinary Drug Handbook 2005, Pharma Vet Inc., Wisconsin, USA, pp. 206-208. Fifth Ed.
101. Radowicz S.N., Power H.T. Long-term use of cyclosporine in the treatment of canine atopic dermatitis. Veterinary Dermatology 2005, 16:81-86.
102. Ramsey I. Ciclosporin BSAVA Small Animal Formulary 2008, British Small Animal Veterinary Association, Cheltenham, UK, pp. 64-66. Sixth Ed.
103. Robson D. Review of the properties and mechanisms of action of cyclosporine with an emphasis on dermatological therapy in dogs, cats and people. Veterinary Record 2003, 152:768-772.
104. Robson D.C., Burton G.G. Cyclosporin: Applications in small animal dermatology. Veterinary Dermatology 2003, 14:1-9.
105. Rosenkrantz W.S. Pemphigus: Current therapy. Veterinary Dermatology 2004, 15:90-98.
106. Rosenkrantz W.S., Griffin C.E., Barr R.J. Clinical evaluation of cyclosporine in animal models with cutaneous immune mediated disease and epitheliotropic lymphoma. Journal of the American Veterinary Medical Association 1989, 25:377-384.
107. Sangalli L., Bortolotti A., Jiritano L., Bonati M. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metabolismand Disposition 1988, 16:749-753.
108. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunology Today 1992, 13:136-142.
109. Seibel W., Sundberg J.P., Lesko L.J., Sauk J.J., McCleary L.B., Hassell T.M. Cutaneous papillomatous hyperplasia in cyclosporine-A treated beagles. Journal of InvestigativeDermatology 1989, 93:224-230.
110. Sihra B.S., Kon O.M., Durham S.R., Walker S., Barnes N.C., Kay A.B. Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax 1997, 52:447-452.
111. Steffan, J., 2004a. Cyclosporine interactions in veterinary medicine; update. In: Proceedings of the Atopica Symposium, Fifth World Congress of Veterinary Dermatology, Vienna, Austria, pp. 28-32.
112. Steffan, J., 2004b. Cyclosporine, an unusual discovery. In: Proceedings of the Atopica Symposium, Fifth World Congress of Veterinary Dermatology, Vienna, Austria, p. 1.
113. Steffan J., Alexander D., Brovedani F., Fisch R.D. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: A parallel, blinded, randomized controlled trial. Veterinary Dermatology 2003, 14:11-22.
114. Steffan J., Maurer G., Rohlfs A. Cyclosporin concentration in the skin following oral administration. Veterinary Dermatology 2003, 14:237-267.
115. Steffan J., Strehlau G., Maurer M., Rohlfs A. Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. Journal of Veterinary Pharmacology and Therapeutics 2004, 27:231-238.
116. Steffan J., Horn J., Gruet P., Strehlau G., Fondati A., Ferrer L., Noli C. Remission of the clinical signs of atopic dermatitis in dogs after cessation of treatment with cyclosporin A or methylprednisolone. Veterinary Record 2004, 154:681-684.
117. Steffan J., Parks C., Seewald W. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. Journal of the American Veterinary Medical Association 2005, 226:1855-1863.
118. Steffan J., Favrot C., Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Veterinary Dermatology 2006, 17:3-16.
119. Stockly I.H. Drug Interactions 1996, The Pharmaceutical Press, London, pp. 604-632. Fourth Ed.
120. Takaori K., Nio Y., Inoue K., Tun T., Fukumoto M., Hashida T., Yasuhara M., Hori R., Tobe T. A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs. Biotherapy 1992, 4:129-137.
121. Takaya S., Iwatsuki S., Noguchi T., Koie H., Zaghloul I., Venkataramanan R., Starzl T.E. The influence of liver dysfunction on cyclosporine pharmacokinetics - A comparison between 70 per cent hepatectomy and complete bile duct ligation in dogs. Japanese Journal of Surgery 1989, 19:49-56.
122. Thelen A., Mueller R.S., Linek M., Peters S., Stechmann K., Steffan J. Influence of food intake on the clinical response to cyclosporin A in canine atopic dermatitis. Veterinary Record 2006, 159:854-856.
123. Vaden S.L. Cyclosporine and tacrolimus. Seminars in Veterinary Medicine and Surgery (Small Animal) 1997, 12:161-166.
124. van den Broek A.H., Kovalik M. The use of ciclosporin in canine and feline dermatology. Part 1. UK Vet 2010, 15:57-66.
125. Venkataramanan R., Perez H.D., Schwinghammer T., Burckart G.J., Ptachcinski R.J., Van Thiel D.H., Starzl T.E. Effect of bile on cyclosporine absorption in dogs. Research Communications in Chemical Pathology and Pharmacology 1986, 53:137-140.
126. Vercelli A., Raviri G., Cornegliani L. The use of oral cyclosporin to treat feline dermatoses: A retrospective analysis of 23 cases. Veterinary Dermatology 2006, 17:201-206.
127. Vickers A.E., Fischer V., Connors S., Fisher R.L., Baldeck J.P., Maurer G., Brendel K. Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metabolism and Disposition 1992, 20:802-809.
128. Vogelnest, L., 2006. Cyclosporine for treatment of atopic dermatitis in the cat - Risk of toxoplasmosis? In: ACVD Dermatology Proceedings 2006, pp. 1-7.
129. Wagner O., Schreier E., Heitz F., Maurer G. Tissue distribution, disposition and metabolism of cyclosporine in rats. Drug Metabolism and Disposition 1987, 15:377-383.
130. Wahlstrom H.E., Lavelle-Jones M., Endres D., Akimoto R., Kolterman O., Moossa A.R. Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dog. Transplantation 1990, 49:600-604.
131. Watkins P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Advanced Drug Delivery Reviews 1997, 27:161-170.
132. Werner A.H. Psoriasiform-lichenoid-like dermatosis in three dogs treated with microemulsified cyclosporine A. Journal of the American Veterinary Medical Association 2003, 223:1013-1016.
133. Whalen R.D., Tata P.N., Burckart G.J., Venkataramanan R. Species differences in the hepatic and intestinal metabolism of cyclosporine. Xenobiotica 1999, 29:3-9.
134. White J.V., Ravis W.R., Nachreiner R., Schall W.D., Walshaw R., Bull R.W. Cyclosporine pharmacokinetics in normal and pancreatectomized dogs. Transplantation 1986, 42:390-395.
135. Winkler M., Ringe B., Oldhafer K., Kattner A., Färber L., Maibücher A., Wonigeit K., Pichlmayr R. Influence of bile on cyclosporin absorption from microemulsion formulation in primary liver transplant recipients. Transplant International 1995, 8:324-326.
136. Wisselink M.A., Willemse T. The efficacy of cyclosporine A in cats with presumed atopic dermatitis: A double blind, randomised prednisolone-controlled study. The Veterinary Journal 2009, 180:55-59.
137. Won Y.H., Sauder D.N., McKenzie R.C. Cyclosporin A inhibits keratinocyte cytokine gene expression. British JournalofDermatology 1994, 130:312-319.
138. Wood A.J., Maurer G., Niederberger W., Beveridge T. Cyclosporine: Pharmacokinetics, metabolism, and drug interactions. Transplantation Proceedings 1983, 15:2409-2412.
139. Young E.W., Ellis C.N., Messana J.M., Johnson K.J., Leichtman A.B., Mihatsch M.J., Hamilton T.A., Groisser D.S., Fradin M.S., Voorhees J.J. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney International 1994, 46:1216-1222.